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Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for
aberrant nuclear export of nucleophosmin leukemic mutants in NPMcAML
Brunangelo Falini, Niccolo` Bolli, Jing Shan, Maria Paola Martelli, Arcangelo Liso, Alessandra Pucciarini, Barbara Bigerna,
Laura Pasqualucci, Roberta Mannucci, Roberto Rosati, Paolo Gorello, Daniela Diverio, Giovanni Roti, Enrico Tiacci,
Giovanni Cazzaniga, Andrea Biondi, Suzanne Schnittger, Torsten Haferlach, Wolfgang Hiddemann, Massimo F. Martelli,
Wei Gu, Cristina Mecucci, and Ildo Nicoletti
We recently identified aberrant cytoplasmic
expression of nucleophosmin (NPM) as the
immunohistochemical marker of a large sub-
group of acute myeloid leukemia (AML)
(about one-third of adultAML) that is charac-
terized by normal karyotype and mutations
occurring at the exon-12 of the NPM gene. In
this paper, we have elucidated the molecular
mechanism underlying the abnormal cyto-
plasmic localization of NPM. All 29 AML-
associated mutated NPM alleles so far iden-
tified encode abnormal proteins which have
acquired at the C-terminus a nuclear export
signal (NES) motif and lost both tryptophan
residues 288 and 290 (or only the residue
290) which determine nucleolar localization.
We show for the first time that both alter-
ations are crucial for NPM mutant export
from nucleus to cytoplasm. In fact, the cyto-
plasmic accumulation of NPM is blocked by
leptomycin-Bandratjadones,specificexpor-
tin-1/Crm1-inhibitors, and by reinsertion of
tryptophan residues 288 and 290, which
respectively relocate NPM mutants in the
nucleoplasm and nucleoli. NPM leukemic
mutants in turn recruit the wild-type NPM
from nucleoli to nucleoplasm and cyto-
plasm. These findings indicate that poten-
tial therapeutic strategies aimed to retarget
NPM to its physiological sites will have to
overcome 2 obstacles, the new NES motif
and the mutated tryptophan(s) at the NPM
mutant C-terminus. (Blood. 2006;107:
4514-4523)
© 2006 by The American Society of Hematology
Introduction
In acute myeloid leukemia (AML), a clinically and molecularly
heterogeneous disease,1 recurrent cytogenetic abnormalities help
define subgroups with different prognosis, and identify patients
who might benefit from targeted therapies.1 However, almost half
adult AMLs display normal karyotype at conventional cytogenet-
ics,2 and the clinical and molecular features of this large subgroup
of patients are still poorly understood.3-7
We recently observed that about 60% of adult AML with normal
karyotype display aberrant cytoplasmic expression of nucleophos-
min (NPM).8 A multifunctional protein9-15 that characteristically
shuttles between the nucleus and the cytoplasm,16 NPM is found
mainly in the nucleolus,17-19 where it is one of the most abundant of
the approximately 700 proteins so far identified by proteomic
techniques.20 Cytoplasmic NPM identifies a distinct subgroup of
AML, named NPMc AML, that accounts for about 35% of all
adult AML and is characterized by wide morphologic spectrum,
multilineage involvement, high frequency of FLT3-ITD mutations,
absence of CD34, and relatively good response to induction
therapy.8 NPMc AML also has a distinct gene expression pro-
file21 and carries mutations in exon-12 of the NPM gene8 that
serve as predictor of favorable prognosis in AML with normal
karyotype,22-24 and as a marker for monitoring of minimal
residual disease.25
In spite of the close association between the aberrant cytoplas-
mic expression of NPM and exon-12 NPM mutations,8 the
mechanism underlying cytoplasmic accumulation of NPM in
leukemic cells and its interference with wild-type NPM protein
remained to be elucidated.
Recently, Nakagawa et al26 asserted that the creation of a
nuclear export signal (NES) motif at the C-terminus of NPM
leukemic mutants (as consequence of the exon-12 NPM mutations)
is alone responsible for cytoplasmic dislocation of NPM. In this
paper, we provide evidence that the new NES motif created by the
mutational event is not in itself sufficient to cause nuclear export of
the NPM leukemic mutants and demonstrate it needs to act in
concert with the mutated tryptophan(s) 288 and 290 at the mutant
C-terminus. These findings have a relevant biological and poten-
tially therapeutic significance.
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Materials and methods
Cells for transfection, primary AML samples, and OCI/AML3
cell line
Transfections were performed on NIH-3T3 murine fibroblasts and human
lung carcinoma H1299 cells. Lymphoprep-isolated leukemic cells for
biochemical studies were obtained from 3 patients with AML carrying NPM
mutation A and 2 patients with AML with wild-type NPM. Bone marrow
trephines from 20 patients with AML (10 with NPM mutations and 10
without NPM mutations) were B5-fixed/decalcified and embedded in
paraffin, as previously described.8 The 10 NPM-mutated cases included 7
mutations A, 1 mutation B, and 2 mutations D. The human AML cell line
OCI/AML3, which carries an exon-12 NPM mutation A,27 was provided by
H. Drexler and grown in alpha–modified Eagle medium (MEM) plus 10%
fetal bovine serum (FBS), 1% glutamine, and antibiotics.
Plasmid constructs
NPM mutants A, B, C, and D were generated by polymerase chain reaction
(PCR) using NPMwt as template; the same forward primer (5-
CGCCACGCTAGCGAAGATTCGATGGAC-3) with different reverse
primers were used for each mutant (mutant A: 5-CTATTTTCTTAAA-
GAGACTTCCTCCACTGCCAGACAGAGATCTTGAATAGCCTCTT-
GG-3; mutant B:5-CTATTTTCTTAAAGAGACTTCCTCCACTGC-
CATGCAGAGATCTTGAATAGCCTCTTGG; mutant C: 5-CTATTTTCT-
TAAAGAGACTTCCTCCACTGCCACGCA GAGATCTTGAATAGC-
CTCTTGG; and mutant D: 5-CTATTTTCTTAAAGAGACTTCCTCCAC
TGCCAGGCAGAGATCTTGAATAGCCTCTTGG). The PCR products of
mutants A, B, C, and D were cloned into the pcDNA3.1/NT-GFP-TOPO
vector (Invitrogen, Carlsbad, CA). To generate the double-flag–HA tag at
the N-terminal of both wild-type NPM and mutant A, PCR was performed
with either wild-type or mutant A as template; 5-CGCCACGCTAGCGAA-
GATTCGATGGAC and 5-TCAAGAATTCCAGAAATGAAATAA-
GACGG were used, respectively, as forward and reverse primers. The PCR
product was excised by NheI and EcoRI, and the resulting fragment was
subcloned into the PCIN4 vector containing the Flag-HA tag at the
N-terminal of the inserted fragment.
Constructs pEGFP-C1-NPM_MUT_A_A290W, pEGFP-C1-
NPM_MUT_A_C288WA290W, and pEGFP-C1-NPM_MUT_A_NO_
2nd_NES were generated using pEGFP-C1-NPMmA8 as a template, by a
set of 2 partially self-complementary primers bearing the desired mutation.
The 2 primers were annealed, and the resulting double-stranded DNA
sequence bearing BglII-EcoRI–compatible ends was ligated into the
pEGFP-C1-NPMmA vector previously digested with the same 2 enzymes,
exploiting the localization of the mutated region between these restriction
sites. The sequences of primers are the following: NPM_
MUT_A_A290W_FOR: 5-GATCTCTGTCTGTGGGTGGAGGAAGT-
CTCTTTAAGAAAATAGG-3; NPM_MUT_A_A290W_REV: 5-AATTC-
CTATTTTCTTAAAGAGACTTCCTCCACCCACAGACAGA-3; NPM
_MUT_A_C288WA290W_FOR: 5-GATCTCTGGCTGTGGGTGGAG-
GAAGTCTCTTTAAGAAAATAGG-3; NPM_MUT_A_C288WA290W_
REV: 5-AATTCCTATTTTCTTAAAGAGACTTCCTCCACCCACAGCC-
AGA-3; NPM_MUT_A_NO_2nd_NES_FOR: 5-GATCTCTGTGGAG-
CAGGGGAGGAAGGCTCTTTAAGAAAATAGG-3; and NPM_MUT_A_
NO_2nd_NES_REV: 5-AATTCCTATTTTCTTAAAGAGCCTTCCTCCCCT-
GCTCCACAGA-3.
pEGFP-C1-NPM mutants E, G, and pEGFP-C1-NPM_MUT_
A_NO_1st_NES were generated with the QuikChange Multi Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA), using pEGFP-C1-NPMwt8 (for
mutants E and G) and pEGFP-C1-NPMmA (for deletion of the first NES) as
a template. The manufacturer’s instructions were followed except for
transformation of bacteria, which was done with 5 L PCR products instead
of 1 L. Primers were designed on the following sequences: NPM-
_MUT_E: 5-GATCTCTGGCAGTCTCTTGCCCAAGTCTCTTTAAG-
3; NPM_MUT_G: 5-GATCTCTGGCAGTGCTTCGCCCAAGTC-
TCTTTAAG-3; and NPM_MUT_A_NO_1st_NES: 5-GCACCAGT-
TATCTGGAAGAACGGGCAGTTTAGGGGCTGG-3. Every construct
was validated by DNA sequencing.
Antibodies
We previously used anti-NPM monoclonal antibodies17,18 that recognize
both wild-type and mutated NPM proteins. To study the NPM mutants without
the interference of wild-type NPM, we generated an affinity-purified
polyclonal antibody (Sil-C) against the synthetic peptide NHCOCH3-
CLAVEEVSLRK-COOH (Inbio-Ltd, Tallin, Estonia) corresponding to
NPM mutant A. The specificity of Sil-C for the NPM mutant was confirmed
by Western blotting (Figure S1, available on the Blood website; see the
Supplemental Figure link at the top of the online article). To assess the
subcellular distribution of wild-type NPM without the interference of
leukemic NPM mutants, we used a mouse monoclonal antibody
(clone FC-61991) that recognizes the wild-type but not mutant NPM
proteins (Invitrogen, Carlsbad, CA). The antinucleolin/C23 monoclonal
antibody, used as a control, was purchased from DakoCytomation
(Glostrup, Denmark).
Inhibition of the Crm1-dependent nuclear export pathway
Expression vectors (5 g) coding HA-NPM wild-type, enhanced green
fluorescent protein (eGFP)–NPMmA, or both were transfected in H1299
cells by the calcium-phosphate precipitation method. After 24 hours, cells
were treated with 20 nM leptomycin B (LMB; Sigma, St Louis, MO) for 8
hours or left untreated. Cells were fixed with 4% paraformadehyde for
immunofluorescence analysis.
NIH-3T3 cells were transfected using Lipofectamine 2000 (Invitrogen)
following manufacturer’s instructions. After 24 hours, cells grown on glass
coverslips were incubated with 10 g/mL cycloheximide (Merck Bio-
sciences, Nottingham, United Kingdom) (30 minutes), and 20 ng/mL LMB
(Merck Biosciences) (5 hours) or 20 ng/mL ratjadones A and C (Alexis
Biochemicals, Carlsbad, CA) (5 hours). For immunofluorescence studies,
cells were fixed in 4% paraformaldehyde (10 minutes). For time-course
experiments, transfected cells were transferred on an Attofluor chamber
(Molecular Probes, Eugene, OR) and observed on a MRC-1024 (BioRad,
Cambridge, United Kingdom) confocal apparatus mounted on an Olympus
IMT-2 microscope with an SPlan 60 /1.4 numeric aperture (NA) oil
objective (Olympus, Tokyo, Japan). Images of a single slice of cells were
recorded in the basal state and after LMB addition at 60-second intervals
using the time-series function of the LaserSharp (BioRad) software. The
488-nm line of an argon laser was used for excitation and a 505-550–nm
band-pass filter on the PMT2 was used for collecting the fluorescence
emission. The images were processed and analyzed with the public-domain
ImageJ software (Rasband WS, Image J; US National Institutes of Health,
Bethesda, MD; http://rsb.info.nih.gov/ij/, 1997-2005). Confocal image
analysis was performed as previously described.27
For Western blot analysis of eGFP-NPM mutant A subcellular distribu-
tion, NIH-3T3 cells transfected with either pEGFP-C1 or pEGFP-C1-
NPMmA were incubated with 20 ng/mL LMB (or vehicle, as control) in
absence of cycloheximide for either 3 or 6 hours. Cells were then harvested,
washed in phosphate-buffered saline (PBS) and lysed in hypotonic buffer
according to the method of Schreiber et al,28 slightly modified. The
supernatant was saved as cytoplasmic fraction. The pellet fraction, contain-
ing nuclei, was washed with hypotonic buffer, solubilized in hypertonic
buffer and boiled in SDS before loading. Equivalent dilutions (representing
equal number of cells) of the cytoplasmic and pellet fractions were
prepared for Western blot analysis of eGFP-NPM mutant A distribution
with an anti-GFP monoclonal antibody (Roche, Indianapolis, IN).
The OCI/AML3 cell line cells were seeded in growth medium (106
cells/mL in 24-well plates) and incubated at 37°C with 5% CO2 for 5 hours.
Following overnight incubation with LMB (20 ng/mL), cells were washed
in PBS, centrifuged, fixed in B5, and embedded in paraffin for immunostain-
ing. Primary leukemic cells from a NPMc patient with AML with a high
peripheral blood count were processed in the same way.
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Immunostaining procedures
For the Flag-HA constructs, H1299-fixed cells were permeabilized with
0.2% Triton-X 100 (10 minutes) and blocked with 10% antigoat serum (30
minutes). Primary antibody anti-HA (1:1000; Roche) was incubated with
cells (1 hour), followed by secondary antibody Alexa 568–conjugated
antirat (1:1000; Molecular Probes) for 30 minutes. Nuclei were visualized
by DAPI staining. Images were collected using a Nikon Eclipse E400
microscope and a 40 /1.3 NA oil objective. Pictures were captured by the
Spot Camera coupled with Spot 4.09 imaging software (Diagnostic
Instruments, Sterling Heights, MI).
The nuclei of NIH-3T3 cells transfected with pEGFP-C1-NPM mutants
and pEGFP-C1-NPMwt were visualized with propidium iodide. pEGFP-C1-
NPM mutants transfected NIH-3T3 were immunostained with a specific
antinucleolin antibody followed by a secondary Texas-Red–conjugated
goat antimouse antibody (Southern Biotechnology Associates, Birming-
ham, AL); nuclei were counterstained with TO-PRO-3 (Molecular Probes).
Paraffin-embedded samples from the OCI/AML3 cell line and 1 patient
with NPMc AML were immunostained with anti-NPM monoclonal
antibody.8,29 The primary antibody was revealed using the immunoalkaline
phosphatase APAAP technique8,29 and hematoxylin counterstain or a
secondary Alexa 488–conjugated goat antimouse antibody (Molecular
Probes) and propidium iodide counterstain.
Cellular extracts, Western blotting, and coprecipitation studies
Nuclear and cytoplasmic extracts were prepared either using the NE-PER
Nuclear and Cytoplasmic Extraction kit (PIERCE Biotechnology, Rock-
ford, IL) or according to the Schreiber’s method,28 slightly modified. For
immunoprecipitation, cells were lysed in 1 mL ice-cold lysis buffer (0.5%
NP-40, 150 mM NaCl, 25 mM Tris [pH 7.5], 1 mM EDTA, 1 mM Na3VO4,
1 g/mL leupeptin, 1 g/mL aprotinin, and 1 mM phenylmethylsulfonyl
fluoride). After incubation on ice (20 minutes), lysates were centrifuged at
14 000g (10 minutes at 4°C) and then incubated with 4 g of either control
immunoglobulin G (IgG), rabbit anti-NPMm (Sil-C), or mouse anti-NPM
(clone 376),8 followed by 30 L Protein A/G Plus–agarose beads (Santa
Cruz Biotechnology, Santa Cruz, CA) rocking overnight at 4°C. Beads were
extensively washed with buffer containing 0.1% NP-40, 150 mM NaCl, 25
mM Tris (pH 7.5), 1 mM EDTA, and inhibitors. Proteins were separated by
SDS–polyacrylamide gel electrophoresis (SDS-PAGE), transferred to poly-
vinylidene difluoride (PVDF; Millipore, Billerica, MA), and probed with
either rabbit polyclonal anti-Crm1 (Santa Cruz Biotechnology) or mouse
monoclonal anti-Crm1 antibody (BD Transduction Laboratories, Palo Alto,
CA), followed by horseradish peroxidase–conjugated secondary antibodies.
Polypeptides were detected using the enhanced chemiluminescence (ECL)
method (Amersham Bioscience, Uppsala, Sweden).
Results
All NPM exon-12 mutations create a leucine-rich NES motif in
the carboxy-terminal portion of the NPM protein
Analysis of the 6 NPM mutant forms (A to F) originally identified
in NPMc AML (Table 1)8 revealed a putative nuclear export
signal (NES) motif26 in the C-terminal portion of NPM proteins,
which was suggested to be responsible for abnormal NPM cytoplas-
mic expression. This hypothesis implies that a NES motif is present
in all NPM mutant proteins generated by NPM exon-12 mutations.
Therefore, we searched for additional exon-12 NPM mutations
in patients with AML. Table 1 lists the 29 NPM mutations that have
been so far identified by mutational screening of a total of 1554
patients with AML.8,22-24,30-32 In addition to the 6 NPM mutants
forms (A to F) we initially reported,8 they include 3 new mutations
(G to I) that we identified in 107 pediatric patients,30 6 new
mutations (Gm to Qm) that we identified in 401 patients with AML
with normal karyotype of the protocol 99 of the German AML
Cooperative Group (AMLCG),23 9 new mutations (numbered in
Table 1 as 1, 3, 4, 6, 7, 12, 13, 10, and 14) reported by Dohner et
al,22 4 new mutations (G† to J†) reported by Suzuki et al,31 and 1
new mutation (I) reported by Verhaak et al.24
We analyzed the NPM mutant proteins derived from the 29
mutation variants listed in Table 1 for the presence of a NES motif,
as defined by a short stretch of amino acids characterized by
multiple hydrophobic residues with typical spacing (eg,
XXXXXX, where  indicates large hydrophobic residues such
as leucine, isoleucine, methionine, valine, or phenylalanine).33
The most frequent NES motif was L-xxx-V-xx-V-x-L that was
present in 20 (69%) of 29 NPM leukemic mutants. Nine (31%) of
the 29 mutants carried a NES motif in which the valine at the
second position of NES motif was replaced with another hydropho-
bic amino acid. In particular, 3 (10.4%) of 29 mutants carried the
L-xxx-L-xx-V-x-L motif; 2 (6.9%) of 29 mutants (Table 1;
mutations G and H) displayed the L-xxx-F-xx-V-x-L motif; 2
(6.9%) of 29 mutants (Table 1; mutations 10 and 14) had the
L-xxx-C-xx-V-x-L motif; and 1 (3.4%) of 29 mutants (Table 1;
mutation 1) exhibited the L-xxx-M-xx-V-x-L motif. Of the 29
mutants, 1 (3.4%) (Table 1; mutation 6), generated by a deletion of
7 nucleotides and insertion of 14 nucleotides, showed at the
C-terminus the sequence LWQDFLNRLFKKIV. Although this
sequence slightly deviates from the accepted NES consensus
L-x-(2,3)-(LIVFM)-x(2,3)-L-x-(LI)33 present in the other 29 mu-
tants, it is still consistent with a leucine-rich NES because of the
presence of 5 hydrophobic residues (leucine and phenylalanine)
within a region of 10 amino acids.34
In conclusion, generation of an additional NES motif in the
C-terminal portion of the NPM protein is one common conse-
quence of NPM exon-12 mutations in NPMc AML.
Export of NPM leukemic mutants is NES dependent
Finding an additional NES motif suggests cytoplasmic dislocation
of NPM may be due to a more active transport of the NPM mutants
by Crm1 (exportin 1),35 the receptor for the NES motif of yeast and
mammalian proteins.36,37
To test this hypothesis, we looked for perturbations in the
nucleo-cytoplasmic transport of NPM mutant proteins in the
presence/absence of the specific Crm1 inhibitor LMB.35 H1299 or
NIH3T3 cells were transfected with plasmids expressing NPM
mutants A to D, fused to enhanced green fluorescent protein
(eGFP), or NPM wild-type as control, and analyzed by immunoflu-
orescence before and after treatment with LMB. In basal condi-
tions, all 4 NPM mutant proteins were localized in the cytoplasm
while NPM wild-type was restricted to the nucleoli, as expected
(Figure 1A). However, LMB treatment completely relocated the
cytoplasmic NPM mutants A to D into the nucleus (Figure 1B).
Identical results (not shown) were obtained in NIH-3T3 cells
transfected with mutant A and treated with ratjadones A and C that
inhibit specifically the Crm138 with the same mechanism as LMB.39
Time course experiments with mutant A showed that about 50% of
protein was relocated in the nucleus at 20 minutes and the process
was completed after 1 hour (Figure 1C-D). Western blot analysis of
eGFP-NPM mutant A subcellular distribution in LMB-treated
NIH-3T3 cells confirmed a time-dependent accumulation of the
intact eGFP-NPM mutant A protein (64 kDa) in the pellet fractions
(containing the nuclei) (Figure 1E). No alteration of eGFP protein
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(27 kDa) localization was observed in LMB-treated cells (only a
mild contamination of the pellet fractions by the overexpressed
protein was detected). In untreated cells, either eGFP or eGFP-
NPM mutant A protein were found (except for the contaminant
part) only in cytoplasmic fractions, as expected.
Confocal microscopy analysis of eGFP-NPM mutant A (L-xxx-
V-xx-V-x-L NES motif) showed that relocalization of the mutated
protein induced by LMB was limited to the nucleoplasm (Figure
2A, top panel). This localization clearly differed from that of
eGFP-NPM wild-type protein which, as expected, was located in
the nucleoli, whether LMB was present or not (Figure 2A, middle
panel). Transient transfection with pEGFP-C1-NPMmA and immu-
nostaining for nucleolin/C23 followed by 3D reconstruction con-
firmed that intranuclear location of NPM mutant A (nucleoplasm,
green) and nucleolin (nucleoli, red) were mutually exclusive
(Figure 2A, lower panel). A nucleoplasmic staining pattern (not
shown) was observed after LMB treatment with 1 rare NPM mutant
bearing the NES motif L-xxx-F-xx-V-x-L (mutant G; Table 1).
LMB also caused nuclear relocation of the mutant NPM in the
OCI/AML3 cells (Figure 2B) that are known to carry the exon-12
mutation A.27 In these cells, Crm1 and NPM mutant A were shown
to coprecipitate, indicating a physical interaction between the 2
molecules (Figure 2C). Leptomycin induced similar nuclear reloca-
tion of NPM in primary leukemic cells of 1 patient with NPMc
AML (not shown).
Finally, the requirement of a NES motif for abnormal cytoplas-
mic expression of NPM was further documented by testing the
subcellular localization of a modified eGFP-NPM mutant A
construct where the 2 valine residues in the NES motif were
replaced by glycines. Transient transfection of NIH-3T3 cells
with this construct showed that the NPM mutant accumulated in
the nucleoplasm, whether LMB was present or not (Figure 3,
right panel).
These results provide evidence that aberrant cytoplasmic localiza-
tion of NPM mutants in NPMc AML is a NES-dependent event.
Two NESs are better than one
The NPM wild-type protein contains a putative physiologic
N-terminus NES motif at position 92-104.40 To assess the contribu-
tion of the physiologic versus additional C-terminus NES motif
created by the mutations in causing abnormal cytoplasmic expres-
sion of NPM, we tested the subcellular localization of modified
eGFP-NPM mutant A constructs where the second and third
hydrophobic residues of the N-terminal or C-terminal NES motif
were replaced by glycines (Figure 3). Transient transfection of
NIH-3T3 with such constructs showed that the NPM mutants
lacking either the physiologic (N-terminus) or the new mutation-
related (C-terminus) NES accumulated in the nucleoplasm (Figure
3, middle and right panels), indicating that the nuclear export and
Table 1. Changes in tryptophans 288 and 290 and creation of a NES motif in NPM mutant proteins generated by 29 NPM exon-12 mutations
in 1554 patients with AML
Mutation Nucleotide sequence Protein sequence
WT* gaccaagaggctattcaagatct ctg gcag t ggaggaagtctctttaagaaaatag 286-DLWQWRKSL
A gaccaagaggctattcaagatct ctgTCTG gcag t ggaggaagtctctttaagaaaatag 286-DLCLAVEEVSLRK
B gaccaagaggctattcaagatct ctgCATG gcag t ggaggaagtctctttaagaaaatag 286-DLCMAVEEVSLRK
C gaccaagaggctattcaagatct ctgCGTG gcag t ggaggaagtctctttaagaaaatag 286-DLCVAVEEVSLRK
D gaccaagaggctattcaagatct ctgCCTG gcag t ggaggaagtctctttaagaaaatag 286-DLCLAVEEVSLRK
E gaccaagaggctattcaagatct ctg gcag t CTCTTGCCCaagtctctttaagaaaatag 286-DLWQSLAQVSLRK
F gaccaagaggctattcaagatct ctg gcag t CCCTGGAGAaagtctctttaagaaaatag 286-DLWQSLEKVSLRK
E• gaccaagaggctattcaagatct ctg gcag t CCCTCGCCCaagtctctttaagaaaatag 286-DLWQSLAQVSLRK
G• gaccaagaggctattcaagatct ctg gcag t GCTTCGCCCaagtctctttaagaaaatag 286-DLWQCFAQVSLRK
H• gaccaagaggctattcaagatct ctg gcag t GTTTTTCAAaagtctctttaagaaaatag 286-DLWQCFSKVSLRK
Gm gaccaagaggctattcaagatct ctgCAGG gcag t ggaggaagtctctttaagaaaatag 286-DLCRAVEEVSLRK
Km gaccaagaggctattcaagatct ctgCCGG gcag t ggaggaagtctctttaagaaaatag 286-DLCRAVEEVSLRK
Lm gaccaagaggctattcaagatct ctgCCGCGGag t ggaggaagtctctttaagaaaatag 286-DLCRGVEEVSLRK
Nm gaccaagaggctattcaagatct ctgCCAG gcag t ggaggaagtctctttaagaaaatag 286-DLCQAVEEVSLRK
Om gaccaagaggctattcaagatct ctgTTTG gcag t ggaggaagtctctttaagaaaatag 286-DLCLAVEEVSLRK
Qm gaccaagaggctattcaagatct ctgTCGG gcag t ggaggaagtctctttaagaaaatag 286-DLCRAVEEVSLRK
1 gaccaagaggctattcaagatct ctg gcagTCCA t ggaggaagtctctttaagaaaatag 286-DLWQSMEEVSLRK
3 gaccaagaggctattcaagatct ctgTCAT gcag t ggaggaagtctctttaagaaaatag 286-DLCHAVEEVSLRK
4 gaccaagaggctattcaagatct ctgCTTG gcag t ggaggaagtctctttaagaaaatag 286-DLCLAVEEVSLRK
6 gaccaagaggctattcaagatct ctg gca AGATTTCTTAAATC gtctctttaagaaaatag 286-DLWQDFLNRLFKKIV
7 gaccaagaggctattcaagatctATGCctg gcag t ggaggaagtctctttaagaaaatag 286-DLCLAVEEVSLRK
12 gaccaagaggctattcaagatct ctgGCCC gcag t ggaggaagtctctttaagaaaatag 286-DLCAAVEEVSLRK
13 gaccaagaggctattcaagatct ctgTAAG gcag t ggaggaagtctctttaagaaaatag 286-DLCKAVEEVSLRK
10 gaccaagaggctattcaagatct ctg gcag tgCTGCTCCC aagtctctttaagaaaatag 286-DLWQCCSQVSLRK
14 gaccaagaggctattcaagatct ctg gcag t TATTTTCCCaagtctctttaagaaaatag 286-DLWQCCSQVSLRK
G† gaccaagaggctattcaagatct ctgTTTG gcag t ggaggaagtctctttaagaaaatag 286-DLCLAVEEVSLRK
H† gaccaagaggctattcaagatct ctgCTTG gcag t ggaggaagtctctttaagaaaatag 286-DLCLAVEEVSLRK
I† gaccaagaggctattcaagatct ctgTAAG gcag t ggaggaagtctctttaagaaaatag 286-DLCKAVEEVSLRK
J† gaccaagaggctattcaagatct ctgTATG gcag t ggaggaagtctctttaagaaaatag 286-DLCMAVEEVSLRK
I‚ gaccaagaggctattcaagatct ctgCAGA gcag t ggaggaagtctctttaagaaaatag 286-DLCRAVEEVSLRK
Mutations A to F refer to those originally identified in Falini et al.8 Mutations from E• to H• refer to those identified in childhood AML cases in Cazzaniga et al.30 Mutations Gm
to Qm refer to those identified in Schnittger et al23 in protocol 99 of the German AML cooperative group; mutations 1, 3, 4, 6, 7, 12, 13, 10 and 14 according to Do¨hner et al22;
mutations G†, I†, H† and J† according to Suzuki et al31; mutation I‚ according to Verhaak et al.24 Lowercase letters in nucleotide sequences indicate wild-type sequence
residues; capital letters, mutated nucleotides. Underlined text indicates leucine-rich NES motif; italics, tryptophan (W) residues.
WT indicates wild type; L, leucin; V, valine; F, phenylalanine; M, methionine; C, cysteine.
*NM_002520.
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cytoplasmic accumulation of NPM mutants can only occur in the
presence of 2 NES motifs (Figure 3, left panel); LMB had no effect
on subcellular localization of the 2 mutants (not shown).
Role of tryptophans 288 and 290 in nucleolar binding and
nuclear export of NPM leukemic mutants
After LMB treatment, NPM mutant A relocated into the nucleo-
plasm but not in the nucleoli (Figure 2A, top and bottom panels).
This finding was not unexpected as both tryptophans 288 and 290
are mutated in this sequence, and the homologous residues in rats
(positions 286 and 288) appear to be critical for nucleolar
localization of wild-type NPM, with mutations of both tryptophans
resulting in nucleoplasmic delocalization of the protein.41
All 29 NPM mutant proteins carried a mutated tryptophan 290,
while tryptophan 288 was retained in 9 (31%) of 29 mutants
(Table 1). Analysis of tryptophan mutations and NES motif
distribution in NPM mutants revealed that the NES most com-
monly found in the NPM mutants (ie, L-xxx-V-xx-V-x-L) is always
associated with mutations of both tryptophans, while tryptophan
288 is retained only in the NPM mutants carrying variants of the
most common NES motif (ie, substitution of the valine at the
second position of NES with leucine, phenylalanine, cysteine, or
methionine).
We used constructs expressing NPM mutant E (Table 1) fused to
eGFP to assess the effect of the single mutation at tryptophan 290
on nucleolar binding. After treatment with LMB, cytoplasmic
mutant E, like mutant A, relocated to the nucleoplasm; however,
mutant E also retained some capability to target nucleoli, as traces
of GFP were detected in these structures (Figure 4). A similar
pattern was observed using a derivative construct of mutant A with
tryptophan 290 reinserted by site-directed mutagenesis (A290W;
Figure 4). Notably, when both tryptophans were reinserted in
mutant A (C288W  A290W), the mutant protein localized com-
pletely to the nucleoli whether LMB was present or not (Figure 4),
suggesting a dose effect for tryptophan molecules.
These findings provide evidence that: (1) tryptophan 290 is
mutated in all NPM leukemic mutants; (2) tryptophan 288 is
retained only in NPM mutants carrying a NES variant other than
the most common motif L-xxx-V-xx-V-x-L; (3) as in the rat,41
tryptophans 288 and 290 are both important for nucleoli targeting;
(4) maximum dislocation of NPM mutants from nucleoli to
nucleoplasm occurs when both tryptophans are mutated; and (5)
NES-dependent nuclear export of the NPM mutant A is blocked
following reinsertion of both tryptophans 288 and 290.
Identification of the mutant NPM protein by a novel specific
antibody
Currently used anti-NPM antibodies17 do not discriminate between
wild-type and mutated NPM proteins, which, since NPM exon-12
mutations are heterozygous,8 are both found in leukemic cells.
Figure 1. Nuclear export of NPM mutants is NES dependent. (A-B) H1299 cells transfected with cDNA encoding for the NPMwt and the NPM mutant proteins A to D8 in the
absence (A) and presence (B) of LMB. eGFP-NPMwt localizes in the nucleoli both in the presence and absence of LMB. In the absence of LMB, all GFP mutants (A-D) show the
expected aberrant cytoplasmic location (A). The same eGFP-mutants are completely relocated in the nucleus in the presence of LMB (B). (C-E) Time-course analysis of LMB
induced nuclear retention of eGFP-NPMmutA in NIH-3T3 cells. (C) Confocal microscope images of NIH-3T3 cells at the indicated time points. E represents the regions (regions
of interest [ROIs]) where the mean fluorescence emission of eGFP-NPMmutA was calculated in the experiment (eg, nucleus [N], cytoplasm [Cy], and the Golgi apparatus [G]).
(D) Time-course measurements of mean fluorescence in the selected areas (ROIs) of NIH-3T3 cells. LMB addition produced a loss of fluorescence in the cytoplasm and Golgi
apparatus and a concomitant increase in the mean fluorescence of the nucleoplasm. ImageJ software was used for the generation of ROIs and time-course analysis. (E)
Western blot analysis of eGFP-NPMmutA subcellular distribution in NIH-3T3 cells with anti-GFP monoclonal antibody. LMB treatment induces a time-dependent accumulation
of eGFP-NPMmutA in the pellet fractions (P). Purity of the subcellular fractions was assessed by stripping the membrane and reblotting with an anti–-tubulin antibody (bottom
panel). Only a nonsignificant contamination was detected for the overexpressed proteins (as evident in the GFP blotting) (middle panel). In untreated cells, eGFP-NPMmutA
(except for the contaminant part) was found only in the cytoplasmic fractions (Cy). The experiment was conducted in absence of cycloheximide so that continuous presence of
GFP-NPMmA in the cytoplasmic fraction during LMB treatment was detected with time.
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Although the NPM mutant constructs localize exclusively in the
cytoplasm in transfected cells,8 subcellular distribution (nuclear vs
cytoplasmic) of NPM mutant proteins in primary NPMc AML
samples could not be investigated because of interference of NPM
wild-type protein. To address this issue, we developed a polyclonal
antibody (Sil-C) specifically directed against NPM mutants. Upon
Western blotting, Sil-C recognized a specific 37-kDa band only in
whole-cell lysates from NPMcAML primary cells (Figure 5A, top
panel; patients 1-3) and not in NPMc– AML samples (patients 4
and 5). Conversely, the anti-NPM monoclonal antibody 376, which
also reacts with wild-type NPM, detected the 37-kDa band in all 5
patients (Figure 5A, bottom panel). In patient 2 (carrying NPM
mutation A), the Sil-C antibody recognized the 37-kDa band only
in the cytoplasm (Figure 5B, top panel) while the 376 antibody
detected it in both nuclear and cytoplasmic fractions, as expected
(Figure 5B, bottom panel).
These findings were confirmed by immunohistochemical stain-
ing of bone marrow biopsies from 10 patients with NPMc AML
(Figure 5C). Interestingly, the Sil-C antibody not only stained the 7
NPMc AMLs carrying the mutation A, but also those carrying the
mutation B (1 case) and D (2 cases). In all samples, Sil-C gave
cytoplasmic-restricted positivity (Figure 5D), which, in competi-
tion experiments, was antagonized by the peptide used as immuno-
gen (not shown). The same peptide did not antagonize cytoplasmic
reactivity of a monoclonal antibody (clone 376) directed against a
different epitope of NPM (not shown). As expected, immunostain-
ing with monoclonal anti-NPM antibodies recognizing wild-type
and mutated NPM17 resulted in nuclear plus cytoplasmic positivity
of the leukemic cells (Figure 5E). The Sil-C antibody did not stain
leukemic cells in any of the 10 AMLs with an unmutated NPM gene
and nucleus-restricted expression of wild-type NPM (NPMc)
used as a negative control (Figure 5F-G).
These findings confirm that the endogenous mutated NPM
proteins localize exclusively in the cytoplasm of primary NPMc
AML cells, suggesting that export of mutated NPM protein from
the nucleus is highly efficient and more rapid than nuclear import.
Figure 2. LMB relocates NPM mutants in the nucleo-
plasm. (A) Confocal microscopy of NIH-3T3 cells trans-
fected with pEGFP-C1-NPMmA or pEGFP-C1-NPMwt in
presence and absence of LMB. In basal conditions, the
mutant A is cytoplasmic (top left) but relocates in the
nucleoplasm (top right) following incubation with LMB.
eGFP-NPMwt localizes in the nucleoli both in the pres-
ence and absence of LMB (middle panel, left and right).
The bottom panel shows LMB-treated cells transfected
with pEGFP-C1-NPMmA (green) and immunostained
with an antinucleolin (C23) monoclonal antibody (Texas
red)–labeling nucleoli (arrow). The nuclear membrane is
blue (TO-PRO-3 staining). After LMB, the eGFP-NPM
mutant A was relocated in the nucleoplasm. Nucleolar
exclusion was confirmed by an electronic cut of the
nucleolar surface (inset in the bottom right figure). (B) The
anti-NPM antibody 376 labels both nucleoli and cyto-
plasm of OCI/AML3 cells in the absence of LMB (left).
Incubation with LMB results in nucleoplasmic relocation
of the cytoplasmic NPM (right). Images were collected as
described27 using a Zeiss Plan Apochromat 100 /1.4
NA oil objective. (C) OCI-AML3 and U937 cell lysates
were subjected to immunoprecipitation (IP) with either
control IgG or rabbit anti-NPMm (Sil-C) and mouse
anti-NPM (Cl. 376): Western blots with anti-Crm1 antibod-
ies are shown in the top panels. Blotting with the anti-
NPMm (Sil-C) and anti-NPM (Cl. 376) antibody are also
shown (middle and bottom panels). WCL indicates OCI-
AML3 whole-cell lysate included as control.
Figure 3. Export of NPM mutants require 2 NES
motifs. Confocal microscope analysis of NIH-3T3 trans-
fected with either pEGFP-C1-NPMmA(left panel), pEGFP-
C1-NPM_MUT_A_NO_1st_NES (middle panel), or
pEGFP-C1-NPM_MUT_A_NO_2nd_NES (right panel).
NPM mutant A containing both NES motifs localizes in the
cytoplasm. Disruption of either N-terminal (middle panel)
or C-terminal (right panel) NES motif in the NPM mutant A
impedes nuclear export of the protein that appears
localized in the nucleoplasm (middle and right panels,
bottom). Images were collected as described27 using a
Zeiss Plan Apochromat 100 /1.4 NA oil objective.
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NPM mutants dislocate NPM–wild type in the nucleoplasm and
cytoplasm
As all mutated NPM proteins conserve the N-terminal dimerization
domain, they may be expected to form heterodimers with wild-type
NPM, as occur with wild-type NPM and NPM-containing fusion
proteins like NPM-ALK and NPM-MLF1.18,42-44
To assess whether delocalized NPM mutant proteins recruit
wild-type NPM from nucleoli, we cotransfected H1299 cells with
vectors encoding for wild-type NPM-HA and mutant A fused to
eGFP. In basal conditions, both mutant (eGFP) and wild-type
(anti-HA) NPM were detected in the cytoplasm, indicating NPM
mutant A delocalized wild-type protein (Figure 6A). Upon treat-
ment with LMB, both mutant and wild-type NPM shuttled to the
nucleoplasm, with some wild-type protein being observed in the
nucleoli (Figure 6A). These findings were confirmed by anti-Flag
immunoprecipitation of Flag-HA-NPM–mutant A or Flag-HA-
NPM-wt–transfected cells, followed by anti-HA and anti-NPM
blotting (Figure 6B). These findings demonstrate that, in transfected
cells, NPM mutants recruit wild-type protein from the nucleoli and
partially delocalize it into the nucleoplasm and cytoplasm.
To investigate whether the wild-type NPM is cytoplasmic-
dislocated even in primary AML cells carrying NPM mutations, we
used the anti-NPM monoclonal antibody (clone FC-61991) that
recognizes the wild-type but not mutant NPM proteins.45 Western
blot and immunohistochemistry studies clearly demonstrated the
endogenous wild-type NPM was localized both in the nucleus and
cytoplasm in NPMc AML primary samples while, as expected,
was restricted to the nucleus in NPMc AML cells (Figure 6C).
A putative mechanism of altered nucleo-cytoplasmic traffic of
the mutated and wild-type NPM proteins in NPMc AML is
depicted in Figure 6D.
Discussion
The present study shows how specific mutations on the NPM
exon-12 sequences severely impair NPM nucleo-cytoplasmic traf-
ficking in transfected cells, AML cell line OCI/AML3 (carrying
exon-12 mutation A), and primary NPMc AML cells. Consequent
to the mutations, 2 major alterations occur at the C-terminus of
NPM leukemic mutants: (1) generation of a leucine-rich NES motif
that reinforces the Crm1-dependent nuclear export of mutated
NPM proteins; and (2) loss of the C-terminus tryptophan(s) residues
that are normally required for NPM binding to the nucleoli.
Figure 4. NES and tryptophan(s) mutations act in concert to export NPM
mutants. Confocal microscope analysis of NIH-3T3 transfected with either pEGFP-
C1-NPMwt or different pEGFP-C1-NPM mutants. NPM mutant A localizes exclusively
in the cytoplasm. The NPM mutant E, retaining tryptophan 288 but lacking tryptophan
290, partially relocalizes in the nucleoli when the nuclear export of the protein is
blocked by LMB treatment. Reinsertion of the tryptophan 290 (NPMmutA, A290W)
produced an almost identical effect. When both tryptophans (288 and 290) were
reinserted in the mutant A, the eGFP-tagged protein totally localized into the nucleoli,
despite the 2 NES motifs, whether LMB was present or not. Images were collected as
described27 using a Zeiss Plan Apochromat 100 /1.4 NA oil objective.
Figure 5. NPM mutants localize exclusively in the cytoplasm of leukemic cells.
(A-B) Western blot analysis (Sil-C vs 376 mAb) of whole-cell lysates from either
NPMc or NPMcAML cells (A) and of nuclear (N) and cytoplasmic (Cy) cell fractions
from a patient with AML bearing NPM mutation A (B). Sil-C recognizes specifically the
mutated NPM protein in the cytoplasmic fraction of NPMc primary leukemic cells.
Results are representative of at least 3 independent experiments. (C-E) Bone marrow
biopsy from a NPMc AML bearing mutation A. (C) Typical appearance of FAB-M5a
type AML; the arrow points to a large leukemic cell with kidney-shaped nucleus. (D)
The Sil-C antibody that recognizes specifically the NPM mutant (NPMm) shows a
cytoplasmic-restricted positivity of leukemic cells (arrow); T indicates a bone
trabecula. (E) Monoclonal anti–NPM 376 that recognizes both the wild-type and
mutant NPM proteins labels leukemic cells both in the cytoplasm and the nucleus
(arrow). (F-G) Bone marrow biopsy from a case of promyelocytic leukemia lacking
NPM mutations (NPMc). (F) Typical appearance of AML FAB-M3 (hematoxylin-
eosin). (G) The Sil-C antibody does not stain leukemic cells (devoid of mutated NPM
protein) and only cross-reacts with a vessel wall; the asterisk indicates the lumen of
the vessel (APAAP technique; hematoxylin counterstain). Images were collected
using an Olympus BX51 microscope and a UPlanFl 100 /1.3 NA oil (C-E) or a
UPlanApo 40 /0.85 (F-G) objective.
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The NPM wild-type protein contains a putative hydrophobic
leucine-rich NES motif (I-xx-P-xx-L-x-L) within residues 94-102
which is conserved from Xenopus laevis to humans.40 Despite the
presence of this motif, the NPM wild-type protein is mainly
localized in the nucleoli suggesting that, in physiologic conditions,
protein import greatly predominates over nuclear export. Interest-
ingly, rat41 and human40 NPM wild-type protein mutants lacking
the 2 tryptophans 288 and 290 delocalize in the nucleoplasm but
not in the cytoplasm,40,41 strongly suggesting that the additional
NES motif reinforces the leukemic NPM mutant ability to be
exported from the nucleus to the cytoplasm. As the NES motif at
the C-terminus of leukemic NPM mutant A is absent in the NPM
wild-type protein, enhanced export could be due to the additive
effects of the 2 NES and/or to an increased affinity of the new NES
motif for Crm1. The results presented in this paper indicates that
cytoplasmic accumulation of NPM mutants depends on the addi-
tive effect of the newly generated C-terminal NES motif.
The tryptophans 288 and 290 both appear to be important for
nucleolar localization, with tryptophan 290 being perhaps more
critical since it is mutated in all NPM mutants so far identified.
Maximal inhibition of nucleolar binding and nucleoplasmic delocal-
ization of mutants is observed when both tryptophans are mutated.
Notably, mutations affecting both tryptophans 288 and 290 were
detected in 20 (69%) of 29 NPM mutants identified to date, and
account for about 95% of all tryptophan mutations found in NPM
leukemic mutants.
The correlation between the type of NES motif and mutations of
tryptophans 288 and 290 is intriguing. The observation that the
NES motif most commonly found in the NPM mutants (ie,
L-xxx-V-xx-V-x-L) is always associated with mutations of both
tryptophans and that tryptophan 288 is retained only in the NPM
mutants carrying variants of the most common NES motif (ie,
substitution of the valine at the second position of NES with
leucine, phenylalanine, cysteine or methionine), suggest a func-
tional difference between the NES motifs.
Taken together, our data clearly show that, for cytoplasmic
accumulation of NPM to occur, the 2 NES motifs and tryptophan(s)
mutations must act in concert. This view clearly differs from that of
Nagakawa et al,26 who claimed the NES motif at the C-terminus
was the only player in cytoplasmic dislocation of NPM leukemic
mutants. The mechanism of altered nucleo-cytoplasmic traffic in
NPMc AML cells also emerges as different to what den Besten et
al45 recently observed in transfected cells. In MT-Arf cells,
leukemic NPM mutant A relocation after incubation with LMB is
reported to be nucleolar, while we clearly demonstrate relocation of
NPM mutant A by Crm1-inhibitors is nucleoplasmic in transfected
Figure 6. NPM mutant A acts as a dominant-negative on wild-type NPM. (A) Cotransfection of H1299 cells with pEGFP-C1-NPMmA and HA-NPM wild-type. About 30% of
cells were transfected and in about 70% of transfected cells the NPM mutant causes partial recruitment of the wild-type NPM from nucleoli to the nucleoplasm and the
cytoplasm. (B) Both FH-NPMwt and FH-NPM mutant A interact with the endogenous NPM in H1299 cells. FH-NPM wt and FH-NPM mutant A plasmids were stably transfected
into H1299 cells. In the left panel, 5% of the whole-cell lysates from stably transfected FH-NPMwt, FH-NPM mutant A, or control H1299 cells were subjected to Western blot with
either 	-NPM or 	-HA. In the right panel, the rest 95% of whole cell lysates were immunoprecipitated with 	-flag (M2), followed by Western blot with either 	-NPM or 	-HA. (C)
Endogenous wild-type NPM protein is dislocated in the cytoplasm of NPMc AML primary samples. In the top panel, nuclear and cytoplasmic extracts from either NPMc or
NPMc AML primary patient cells were subjected to Western blot analysis with either the anti-NPM mouse monoclonal antibody (clone FC-61991) from Invitrogen (anti-NPM
wt) or the Sil-C antibody (anti-NPMm). A strong signal for NPMwt was evident in both the nuclear and cytoplasmic fraction of AML cells carrying NPM mutation but only in the
nuclear fraction of NPMc– AML cells. The lower panel shows immunohistochemical study of 2 different AML samples with the anti-NPMwt antibody. The NPMc AML sample
expresses the wild-type NPM both in the nucleus and cytoplasm (arrow). In contrast, the NPMc– AML sample shows the expected nucleus-restricted expression of wild-type
NPM (arrow). Images were collected using an Olympus BX61 microscope and a UPlanFl 100 /1.3 NA objective. (D) Hypothetical mechanism of altered nucleo-cytoplasmic
traffic of NPM mutant A and wild-type NPM. Red circles indicate tryptophan residues; black circles, mutated tryptophans; magenta boxes, NES motif; blue boxes, mutated NPM
protein; and green boxes, wild-type NPM protein. To simplify, the scheme shows only the binding of Crm1 to the mutant NES but not to the physiologic one, nor to the full ternary
complex (Crm1-NES-ranGTP). NLS indicates nuclear localization signal.
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NIH-3T3 cells. Several points need to be borne in mind when
analyzing these discrepancies. Like Nakagawa et al,26 den Besten
et al45 appear to disregard or underestimate the role of mutated
tryptophan(s) 288 and 290 in the altered nucleo-cytoplasmic
transport of NPM leukemic mutants. Artificial interference by the
Arf protein in MT-Arf cells used by den Besten et al45 may be
another factor. Finally, den Besten et al45 show that much wild-type
NPM protein is delocalized in the cytoplasm by the NPM mutant A.
Our immunohistologic studies of bone marrow biopsies using
anti-NPM antibodies, including reagents specific for the wild-type
and mutated NPM proteins, confirm the presence of cytoplasmic-
dislocated wild-type NPM in primary NPMc AML cells, but also
reveal that a residue of wild-type NPM remains in the nucleus
(Figure 6C, bottom panels). Further studies are required to exactly
quantify by fluorescence-based techniques the ratio of wild-type to
mutated NPM in the subcellular compartments of NPMc primary
leukemic cells.
Based on these findings, the following scenario can be envis-
aged. Mutated NPM proteins that retain the 2 nuclear localization
signals (NLSs) enter the nucleus. Their capability to bind nucleoli
is hindered completely (when both tryptophans are mutated) or
partially (when only tryptophan 290 is altered). Nucleoplasmic
NPM mutants may become easily available for binding to Crm1
roaming in the nucleoplasm46 through the NES motifs. NPM
mutants accumulate in the cytoplasm most likely because the
NES-Crm1–mediated nuclear export of mutants is more efficient
than nuclear import. The NPM leukemic mutants cause in turn
partial delocalization of the NPM wild-type protein from the
nucleus to the cytoplasm.
Our demonstration that antibodies can be produced to react with
mutant, but not with wild-type, NPM proteins is of biological
interest and potential clinical relevance. It might be feasible in the
future to use intracellular antibodies (“intrabodies”)47 against NPM
mutants to ablate protein function as an alternative to gene-based
knockout technologies which do not appear to discriminate be-
tween wild-type and mutated NPM encoding RNAs (B.F. and A.L.,
unpublished observations, June 2005). The OCI/AML3 cell line
may well serve as a preclinical model for screening intrabodies and
other compounds designed to interfere with the NPM-altered
nucleo-cytoplasmic traffic.
The NPM wild-type protein plays a critical role in the control of
hematopoiesis (especially erythropoiesis) during embryonic devel-
opment,15 and is involved in regulation of the Arf-p53 path-
way9,11-14 and centrosome duplicaton.10,40 Our finding that in
transfected cells NPM mutants recruit wild-type NPM to the
nucleoplasm and cytoplasm suggests they interfere with native
protein functions and could contribute to AML. However, exactly
how the mutants exert their putative leukemogenic action remains
elusive. Den Besten et al45 showed that NPM mutant proteins
dislocate both wild-type NPM and the Arf protein into the
cytoplasm, but were unable to demonstrate any transforming
activity of the NPM mutants in NIH-3T3 and in Atm-null MEF
cells. These findings suggest that NPM mutants could exert their
transforming activity in a tissue-specific manner, an issue that
needs to be addressed using appropriate animal models. Animal
models show that AML may arise as result of the cooperative effect
of different genetic lesions (eg, FLT3-ITD mutations in combina-
tion with molecular alterations, such PML-RAR alpha or AML1-
ETO fusion genes).1 We previously demonstrated that FLT3-ITD
mutations in AML with normal karyotype occur twice as frequently
in cases with NPM mutations as in those without.8 Consequently, a
major focus of future studies should be to determine whether
interactions between FLT3-ITD and NPM mutations contribute to
the leukemogenesis. Although at present there is no evidence for
the leukemogenic potential of NPM mutations, if it should be
demonstrated in the future, then retargeting NPM mutants to their
physiologic cell compartment (nucleoli) might be a potential
therapeutic strategy.36,37 This paper clearly shows that, to be
successful, retargeting has to overcome 2 obstacles, the new NES
motif and the mutated tryptophan(s) at the mutant C-terminus.
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